News

Active Biotech Interim Report January – June 2020

Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma

Tasquinimod demonstrates potent anti-tumor activity in experimental models for multiple myeloma. Data will be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting, taking place June 11-21 2020

Presentation – new direction

New pre-clinical data on laquinimod in an experimental autoimmune uveitis model has been published as an abstract in the Journal of Immunology. May 1, 2020, 204 (1 Supplement) 150.18.

Active Biotech provides status update in the portfolio projects

Annual General Meeting of Active Biotech AB

Annual Report 2019

Active Biotech AB – Interim report January – March 2020

Notice of annual general meeting of shareholders on Tuesday, May 19, 2020

Active Biotech AB – Year-end report January – December 2019

Active Biotech announces new direction

Active Biotech’s election committee appointed

Active Biotech Interim report January – September 2019

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

Active Biotech AB: Interim report January – June 2019

The Annual General Meeting of Active Biotech was held on May 23, 2019

The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019

The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board

Annual Report 2018 Active Biotech AB (publ)

Active Biotech AB – Interim report January – March 2019

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Active Biotech completes sale of property

An Extraordinary General Meeting of Active Biotech AB was held on April 4, 2019

Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019

Active Biotech Year-end report January – December 2018

Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

Active Biotech has received an indicative bid for the property in Lund – the Board is positive

Active Biotech provides updated information about the company’s financial position

Interim report January – September 2018

New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018

<\span>

Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”

Active Biotech regains global rights to development and commercialization of laquinimod

Active Biotech AB – Interim Report January – June 2018

Active Biotech provides update on laquinimod in Huntington’s disease

The Annual General Meeting of Active Biotech was held on May 17, 2018

Annual Report 2017 Active Biotech AB (publ)

Notice of Annual General Meeting of Shareholders May 17, 2018, at 5 pm

Active Biotech’s rights issue over subscribed

Active Biotech’s partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer

Prospectus relating to Active Biotech’s rights issue published

Extraordinary General Meeting of Active Biotech AB

Active Biotech carries out rights issue

Active Biotech AB Year-end report January – December 2017